ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1430

Autoantibodies Stabilize Neutrophil Extracellular Traps in COVID-19

Yu Zuo1, Srilakshmi Yalavarthi1, Sherwin Navaz1, Claire Hoy1, Alyssa Harbaugh1, Kelsey Gockman1, Melanie Zuo1, Jacqueline Madison1, Hui Shi1, Yogendra Kanthi2 and Jason Knight1, 1University of Michigan, Ann Arbor, MI, 2NHLBI, NIH, Bethesda, MD

Meeting: ACR Convergence 2021

Keywords: Autoantibody(ies), COVID-19, neutrophils

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 8, 2021

Title: Abstracts: Innate Immunity (1430–1433)

Session Type: Abstract Session

Session Time: 10:30AM-10:45AM

Background/Purpose: The release of neutrophil extracellular traps (NETs) by hyperactive neutrophils is recognized to play an important role in the thromboinflammatory milieu inherent to severe presentations of COVID-19. At the same time, a variety of functional autoantibodies have been observed in individuals with severe COVID-19 where they likely contribute to immunopathology. Work by our group and others has found that many hospitalized COVID-19 patients develop antiphospholipid antibodies similar to those found in antiphospholipid syndrome (APS). Patients with APS (as well as lupus and ANCA-associated vasculitis) have also been reported to develop autoantibodies targeting NETs, which impair NET clearance and activate complement. Here, we aimed to determine the extent to which autoantibodies might target NETs in COVID-19 and, if detected, to elucidate their clinical associations and potential functions.

Methods: NETs were solubilized and coated onto ELISA plates. We then measured IgG and IgM global anti-NET activity in 328 individuals hospitalized with COVID-19 alongside 48 healthy controls. The ability of COVID sera and purified anti-NET antibodies to protect NETs from degradation was determined. We assessed complement deposition on NETs by immunofluorescence microscopy.

Results: We found elevated levels of anti-NET IgG and IgM in patients with COVID-19 as compared with healthy controls (p< 0.0001 for both IgG and IgM) (Figure 1A-B). Using a cutoff of 2 standard deviations above the control mean, 27% of patients were positive for anti-NET IgG and 60% for anti-NET IgM. There was a strong interrelationship between anti-NET IgG and anti-NET IgM (r=0.4, p< 0.0001). High anti-NET antibody levels associated with circulating markers of NETs. Specifically, anti-NET IgG and IgM levels were positively correlated with myeloperoxidase-DNA complexes (IgG r=0.31, p< 0.0001; IgM r=0.41, p< 0.0001) and calprotectin (IgG r=0.33, p< 0.0001; IgM r=0.34, p< 0.0001). Clinically, anti-NET antibodies tracked with impaired oxygenation efficiency defined as SpO2/FiO2 ratio (IgG r=-0.17, p=0.018; IgM r=-0.30, p< 0.0001) and elevated levels of circulating D-dimer (IgG r=0.33, p< 0.0001; IgM r=0.19, p=0.0012). Furthermore, patients who required mechanical ventilation had higher levels of anti-NET antibodies than those who did not require oxygen supplementation (IgG p=0.0013; IgM p< 0.0001). Mechanistically, levels of anti-NET IgG in particular demonstrated a negative correlation with the NET degradation potential of COVID sera (Figure 1C), while purified IgG from high anti-NET sera impaired the ability of DNases in healthy serum to degrade NETs (Figure 1D). As compared with low anti-NET COVID sera, high anti-NET sera also more efficiently deposited complement C3d on NETs (Figure 2).

Conclusion: In summary, these data reveal high levels of anti-NET antibodies in many individuals hospitalized with COVID-19, where they track with NETs themselves and also disease severity. It is likely that these antibodies impair NET clearance and potentiate complement activation, which may together conspire to potentiate SARS-CoV-2-mediated thromboinflammation.

Figure 1. A-B, Anti-NET IgG/M levels were compared by Mann-Whitney test; ****p < 0.0001. Dotted lines indicate positive threshold set at 2 standard deviations above the control mean. C, Freshly-induced NETs were incubated with sera from COVID_19 patients. After 90 minutes, percent residual NETs were determined. Correlation with anti-NET IgG was determined by Spearman’s method. D, Freshly-induced NETs were incubated with control serum supplemented with either purified IgG from COVID patients or controls, and percent residual NETs were determined after 90 minutes. COVID IgG was compared to control by one-way ANOVA; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.

Figure 2. Control neutrophils were stimulated with PMA to generate NETs. After fixation with paraformaldehyde, NETs were incubated with sera from patients with high (top panels) or low (bottom panels) anti-NET IgG; scale bars=100 microns.


Disclosures: Y. Zuo, None; S. Yalavarthi, None; S. Navaz, None; C. Hoy, None; A. Harbaugh, None; K. Gockman, None; M. Zuo, None; J. Madison, None; H. Shi, None; Y. Kanthi, None; J. Knight, None.

To cite this abstract in AMA style:

Zuo Y, Yalavarthi S, Navaz S, Hoy C, Harbaugh A, Gockman K, Zuo M, Madison J, Shi H, Kanthi Y, Knight J. Autoantibodies Stabilize Neutrophil Extracellular Traps in COVID-19 [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/autoantibodies-stabilize-neutrophil-extracellular-traps-in-covid-19/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/autoantibodies-stabilize-neutrophil-extracellular-traps-in-covid-19/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology